Financial Performance - Net profit attributable to shareholders for Q1 2024 was CNY 20,364,812.90, representing a 47.65% increase year-over-year[12] - Operating revenue for Q1 2024 reached CNY 268,085,106.42, marking a 31.98% increase compared to the same period last year[12] - The company reported a profit before tax of ¥23,109,805.28 for Q1 2024, up from ¥15,996,284.83 in Q1 2023, indicating a growth of approximately 44.0%[43] - The total profit for Q1 2024 was ¥21.16 million, an increase of 24.8% from ¥16.99 million in Q1 2023[45] - The company reported a significant reduction in short-term borrowings from ¥12,735,307.30 to ¥2,968,800.00, a decrease of approximately 76.70%[37] Assets and Liabilities - Total assets as of March 31, 2024, were CNY 830,305,536.50, a slight decrease of 0.001% compared to the end of 2023[12] - The company's total liabilities to assets ratio decreased to 36.98% from 39.31% year-over-year[12] - Total current assets as of March 31, 2024, amounted to ¥554,423,079.09, a decrease from ¥569,713,888.04 as of December 31, 2023, representing a decline of approximately 2.54%[36] - Total liabilities decreased to ¥307,043,684.26 from ¥326,426,328.25, a reduction of approximately 5.93%[38] - Total equity attributable to shareholders increased to ¥523,261,441.05 from ¥502,891,119.69, reflecting an increase of about 4.73%[38] Cash Flow - The company's net cash flow from operating activities was CNY 8,428,855.39, down 43.71% from the previous year[12] - Net cash flow from operating activities was $7,538,420.14, a decrease of 38.5% compared to $12,321,587.29 in the previous period[51] - Total cash outflow from investing activities was $95,289,936.43, down from $108,349,384.71, resulting in a net cash flow from investing activities of -$51,044,958.93[51] - Cash and cash equivalents at the end of the period totaled $45,442,952.70, significantly lower than $132,932,931.51 at the beginning of the period[51] - Cash paid for employee compensation was $27,297,962.59, up from $17,044,877.42, indicating a 60.5% increase[51] Research and Development - Research and development expenses increased by 51.58% to CNY 9,465,221.90, driven by investments in new product development[14] - Research and development expenses for Q1 2024 were ¥9,465,221.90, compared to ¥6,244,397.97 in Q1 2023, marking an increase of about 51.5%[42] - Research and development expenses increased to ¥8.48 million in Q1 2024, up from ¥6.02 million in Q1 2023, reflecting a 41.0% rise[45] Shareholder Information - The total number of ordinary shares is 90,666,700, with 73.10% being restricted shares[22] - The largest shareholder, Hu Xiang, holds 44.53% of the shares, totaling 40,370,207 shares[25] - There are no pledges or judicial freezes on shares held by major shareholders[27] Compliance and Commitments - The company has complied with all disclosed commitments without any overdue situations[31] - The company has no litigation or arbitration matters during the reporting period[30] - The company has not engaged in any share buyback activities during the reporting period[30] Other Financial Metrics - The weighted average return on equity based on net profit attributable to shareholders was 3.97%, up from 2.97% in the previous year[12] - Basic and diluted earnings per share for Q1 2024 were both ¥0.22, an increase from ¥0.15 in Q1 2023[44] - Non-recurring gains and losses for the period amounted to CNY 693,147.80 after tax[17] - The company’s financial expenses showed a notable decrease, with interest expenses at ¥11.95 thousand in Q1 2024, down from ¥267.82 thousand in Q1 2023[45]
合肥高科(430718) - 2024 Q1 - 季度财报